152 related articles for article (PubMed ID: 38562075)
1. Anti-CD19 chimeric antigen receptor T-cell therapy for B-cell acute lymphoid leukemia.
Rapoport AP
Haematologica; 2024 Apr; 109(4):1019-1020. PubMed ID: 38562075
[No Abstract] [Full Text] [Related]
2. Immunophenotypic changes in leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia after treatment with CD19-directed chimeric antigen receptor (CAR)- expressing T cells.
Mikhailova E; Illarionova O; Shelikhova L; Zerkalenkova E; Molostova O; Olshanskaya Y; Novichkova G; Maschan A; Maschan M; Popov A
Haematologica; 2022 Apr; 107(4):970-974. PubMed ID: 34911282
[No Abstract] [Full Text] [Related]
3. Donor origin CAR19 T cell infusion for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation.
Yang X; Dai H; Kang L; Qu C; Li Z; Yin J; Qiu H; Fu C; Han Y; Jin Z; Ma X; Zhu X; Yu L; Wu D; Tang X
Hematol Oncol; 2019 Dec; 37(5):655-658. PubMed ID: 31656047
[No Abstract] [Full Text] [Related]
4. Genetic Mechanism of Leukemia Relapse Following CD19 Chimeric Antigen Receptor T Cell Therapy.
Qiu S; Pan Y; Shi S; Omotoyosi FF; Chen K; Guo Z; Lü P
Cancer Biother Radiopharm; 2022 Jun; 37(5):335-341. PubMed ID: 33739864
[TBL] [Abstract][Full Text] [Related]
5. How to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemia.
Ruella M; Gill S
Expert Opin Biol Ther; 2015 Jun; 15(6):761-6. PubMed ID: 25640460
[TBL] [Abstract][Full Text] [Related]
6. Impact of age on efficacy and safety of chimeric antigen receptor-T in B-cell acute lymphoblastic leukaemia-A systematic review and meta-analysis.
Wu JF; Abid H; Szabo A; Abid MB
Br J Haematol; 2023 Dec; 203(5):e117-e120. PubMed ID: 37814795
[No Abstract] [Full Text] [Related]
7. Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia.
Gupta S; Kohorst M; Alkhateeb HB
Eur J Haematol; 2024 Jan; 112(1):51-63. PubMed ID: 38105391
[TBL] [Abstract][Full Text] [Related]
8. Chimeric Antigen Receptor T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: Current Landscape in 2021.
Gauthier J; Turtle CJ
Cancer J; 2021 Mar-Apr 01; 27(2):98-106. PubMed ID: 33750068
[TBL] [Abstract][Full Text] [Related]
9. Optimizing CAR-T cell therapy in adults with B-cell acute lymphoblastic leukemia.
Agrawal V; Murphy L; Pourhassan H; Pullarkat V; Aldoss I
Eur J Haematol; 2024 Feb; 112(2):236-247. PubMed ID: 37772976
[TBL] [Abstract][Full Text] [Related]
10. CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report.
Sun Y; Su Y; Wang Y; Liu N; Li Y; Chen J; Qiao Z; Niu J; Hu J; Zhang B; Ning H; Hu L
Front Immunol; 2021; 12():728962. PubMed ID: 34691036
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia.
Ceppi F; Gardner RA
Cancer J; 2019; 25(3):191-198. PubMed ID: 31135526
[TBL] [Abstract][Full Text] [Related]
12. Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights.
Obstfeld AE; Frey NV; Mansfield K; Lacey SF; June CH; Porter DL; Melenhorst JJ; Wasik MA
Blood; 2017 Dec; 130(23):2569-2572. PubMed ID: 29074500
[No Abstract] [Full Text] [Related]
13. Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.
Zhang J; Yang F; Qiu HY; Wu Q; Kong DQ; Zhou J; Han Y; Wu DP
Leuk Lymphoma; 2019 Jun; 60(6):1454-1461. PubMed ID: 30714847
[TBL] [Abstract][Full Text] [Related]
14. [Chimeric antigen receptor (CAR) T cells targeting CD19 for acute lymphoblastic leukemia].
Takahashi Y; Nishio N
Rinsho Ketsueki; 2023; 64(9):1184-1191. PubMed ID: 37899199
[TBL] [Abstract][Full Text] [Related]
15. Advances in the development of chimeric antigen receptor-T-cell therapy in B-cell acute lymphoblastic leukemia.
Zhang X; Li JJ; Lu PH
Chin Med J (Engl); 2020 Feb; 133(4):474-482. PubMed ID: 31977556
[TBL] [Abstract][Full Text] [Related]
16. The use of chimeric antigen T-cell therapy in chronic lymphocytic leukemia.
Siddiqi T
Clin Adv Hematol Oncol; 2022 Jun; 20(6):366-368. PubMed ID: 35731607
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of chimeric antigen receptor T-cell therapy targeting CD19/CD22 in refractory/relapsed transformed aggressive B-cell lymphoma.
Xu H; Lv Q; Huang L; Cao W; Wang J; Meng F; Li C; Zheng M; Chen L; Mu K; Cheng J; Zhu L; Zhou J; Zhang Y; Wang N; Cao Y
Cytotherapy; 2023 Feb; 25(2):185-191. PubMed ID: 36283943
[No Abstract] [Full Text] [Related]
18. [Consensus of Chinese experts on chimeric antigen receptor T cell therapy for adult acute B-cell lymphoblastic leukemia (2022)].
;
Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):89-95. PubMed ID: 35381667
[No Abstract] [Full Text] [Related]
19. CD19 chimeric antigen receptor T-cell therapy in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia without complete molecular response at 3 months.
Yao Z; Gu B; Chen J; Xu Y; Chen F; Xue S; Qiu H; Tang X; Han Y; Chen S; Sun A; Yu L; Zhang Y; Wu D; Wang Y
Blood Cancer J; 2023 May; 13(1):75. PubMed ID: 37164955
[No Abstract] [Full Text] [Related]
20. Trafficking of CAR T cells to sites of subclinical leukaemia cutis.
O'Reilly M; Roddie C; Marzolini MAV; Rodriguez-Justo M; Pomplun S; Pule M; Peggs KS
Lancet Oncol; 2020 Mar; 21(3):e179. PubMed ID: 32135121
[No Abstract] [Full Text] [Related]
[Next] [New Search]